Ignite Creation Date:
2025-12-24 @ 3:43 PM
Ignite Modification Date:
2026-01-03 @ 9:22 PM
Study NCT ID:
NCT05884892
Status:
RECRUITING
Last Update Posted:
2023-06-01
First Post:
2022-12-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Egyptian Hypertrophic Cardiomyopathy Program
Sponsor:
Magdi Yacoub Heart Foundation
Organization:
Study Overview
Official Title:
Egyptian Hypertrophic Cardiomyopathy Program
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.
Detailed Description:
This project aims to:
* Define incidence, severity, phenotype, genotype and determinants of the disease in Egypt.
* Characterise the phenotype and genotype of several large cohorts with inherited muscle disease and their relatives.
* Provide state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.
* Study the basic mechanisms responsible for the different phenotypes at a molecular and cellular level including genotype-phenotype correlation.
* Provide a special focus for studying patients who are genotype positive and phenotype negative which we believe could yield critical data regarding the evolution of the disease.
* Develop sophisticated laboratory studies for single cell electrophysiology and immunocytochemistry and others focusing on the explanted human material from the surgical program.
* Define the role of microvascular coronary artery in the development and progression of the disease.
* Training Egyptian cardiologists, cardiac surgeons and scientists on state-of-the-art diagnosis and management of heart muscle disease including the latest developments in imaging, novel surgical techniques, coronary physiology, next generation sequencing, bioinformatics and cellular electrophysiology.
* Define incidence, severity, phenotype, genotype and determinants of the disease in Egypt.
* Characterise the phenotype and genotype of several large cohorts with inherited muscle disease and their relatives.
* Provide state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.
* Study the basic mechanisms responsible for the different phenotypes at a molecular and cellular level including genotype-phenotype correlation.
* Provide a special focus for studying patients who are genotype positive and phenotype negative which we believe could yield critical data regarding the evolution of the disease.
* Develop sophisticated laboratory studies for single cell electrophysiology and immunocytochemistry and others focusing on the explanted human material from the surgical program.
* Define the role of microvascular coronary artery in the development and progression of the disease.
* Training Egyptian cardiologists, cardiac surgeons and scientists on state-of-the-art diagnosis and management of heart muscle disease including the latest developments in imaging, novel surgical techniques, coronary physiology, next generation sequencing, bioinformatics and cellular electrophysiology.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: